Contact Us
Drug Search Results
More Filters [+]

NN-9925

Alternative Names: nn-9925, nn9925, nn 9925
Latest Update: 2017-02-28
Latest Update Note: Clinical Trial Update

Product Description

Novo Nordisk was developing nn-9925, an oral GLP-1 Agonist for Diabetes Mellitus, Type 2

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NN-9925

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NN9925-3779

P1

Completed

Type 2 Diabetes

2010-09-16

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions